Groningen

• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies Ended
  2024-515827-12-00 1 2020-01-28 Acute Myeloid Leukemia (AML)
• A study to Evaluate Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended
  2023-508364-29-00 5 2019-11-22 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced Ended
  2023-506657-38-00 5 2019-10-02 Biliary Tract Carcinoma
• FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial Ended
  2024-518036-36-03 6 2019-09-20 Breast cancer
• A study comparing combination of Encorafenib + Binimetinib in Patients with BRAF V600-mutant Non-small Cell Lung Cancer. Ended
  2024-515929-28-00 4 2019-08-02 Non-small Cell Lung Cancer
• OPTIMIZE Ended
  2024-516509-22-00 6 2019-07-22 kidney transplant
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• A phase 1 study of oral Debio 0123 in combination with carboplatin in patients with advanced solid tumors Ended
  2024-510984-52-00 1 2019-05-24 Patients with tumors
• HELIOS-A: A Phase 3 Global Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis Ended
  2023-508365-33-00 5 2019-04-09 Hereditary Transthyretin Amyloidosis
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 5 2019-01-09 Moderate and Severe Atopic Dermatitis
• A phase III trial investigating a gene therapy (AAV-hFIXco-Padua, AMT061), in adult patients with severe or moderately severe haemophilia B, … Ended
  2024-510738-42-00 5 2018-12-03 Haemophilia B
• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended
  2023-506641-35-00 4 2018-07-09 Relapsed/Refractory Mantle Cell Lymphoma
• Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. Ended
  2024-511050-44-00 4 2018-05-16 Precursor B-acute lymphoblastic leukemia
• A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who … Ended
  2023-510557-42-00 4 2017-07-10 chronic lymphocytic leukemia
• CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 901 Ended
  2022-501784-40-00 5 2017-05-26 Untreated Unresectable or Metastatic Urothelial Cancer
• A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha … Ended
  2024-511967-26-00 5 2016-11-21 AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)
• GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL) Ended
  2024-511048-22-00 4 2016-10-27 Chronic lymphocytic leukemia
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• Tepotinib Phase II study in advanced lung cancer harboring MET exon 14 (METex14) skipping alterations and MET amplification Ended
  2024-512003-39-00 4 2016-07-18 Lung Cancer
• A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended
  2023-509360-24-00 5 2016-06-16 Subjects with resected adenocarcinoma or squamous cell carcinoma esoph
• A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can … Ended
  2024-517856-36-00 5 2015-03-09 Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce
• A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended
  2023-504761-23-00 5 2014-11-19 Advanced or metastatic renal cell carcinoma
• A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma Ended
  2023-503348-15-00 7 Hodgkin lymphoma or non-Hodgkin lymphoma

Showing 649–672 of 679 trials